Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 19/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 19/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 19/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 19/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378804 | 0.80 | ALOX5 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25965933 | 0.76 | ALOX5 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12372623 | 0.76 | ALOX5 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL31127631 | 0.73 | CHRNB4 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19464246 | 0.73 | ALOX5 (0.43) | — | |
| SCHEMBL21683097 | 0.73 | ALOX5 (0.43) | — | |
| SCHEMBL19690169 | 0.72 | ALOX5 (0.54) | — | |
| SCHEMBL22055528 | 0.72 | ALOX5 (0.54) | — | |
| SCHEMBL19690171 | 0.72 | ALOX5 (0.54) | — | |
| SCHEMBL651805 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | CHRNB2 4751/4885CHRNB4 4815/4885CHRNA3 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.